Financial overview

Scandion Oncology financial report data and keyfigures. History for income statement, balance sheet and cash flow.

Pre
Pre
Pre

Description

Scandion Oncology is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has been used in certain standard cancer treatments during preclinical studies. The company was founded in 2017 and is headquartered in Copenhagen, Denmark.

Biotechnology